Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Aradigm Corporation (OTC BB: ARDM.OB) (the “Company”) today announced financial results for the second quarter and six months ended June 30, 2013.
Total revenue was approximately $0.2 million for both the second quarter of 2013 and the second quarter of 2012. Revenue in both quarters reflects the quarterly royalty payment from Zogenix for product sales of SUMAVEL® DosePro™ needle-free delivery system for treatment of acute migraine and cluster headaches.
Hey, check out all the research scientist jobs. Post your resume today!
